EGFR and colorectal carcinoma: For the others, the targeted therapy (TT) consisting of the BRAF inhibitor encorafenib plus the anti-epidermal growth factor receptor (anti-EGFR) cetuximab is the current standard of care, based on the results of the randomized phase III BEACON CRC trial that demonstrated a statistically and clinically significant benefit from encorafenib plus cetuximab over standard irinotecan-based chemotherapy plus cetuximab in terms of overall survival (OS), overall response rate, and progression-free survival (PFS) in pretreated patients with BRAFV600E-mutated mCRC.9